Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix

NCT00946556 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Herpes Simplex Type Two Infection
HIV Infections

Interventions

DRUG: Valacyclovir
DRUG: Placebo

Sponsor

University of Toronto